Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, double-dummy, oral donepezil controlled study on the safety and efficacy of repeated monthly subcutaneous injections of a sustained-release implant of ZT 1 [DEBIO 9902; Debiopharm] in patients with moderate Alzheimer's disease.

Trial Profile

A randomised, double-blind, double-dummy, oral donepezil controlled study on the safety and efficacy of repeated monthly subcutaneous injections of a sustained-release implant of ZT 1 [DEBIO 9902; Debiopharm] in patients with moderate Alzheimer's disease.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mimopezil (Primary) ; ZT-01 (Primary) ; ZT-01 (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms BRAINz
  • Most Recent Events

    • 31 Mar 2020 According to a Zucara Therapeutics, it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund.The proceeds from the financing will fund this trial
    • 30 Oct 2009 Additional lead trial investigator Wilkinson D identified as reported by United Kingdom Clinical Research Network record.
    • 22 Sep 2009 Actual end date changed from June 2009 to Sep 2009 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top